Multidisciplinary approach to osteosarcoma.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 10. Curr Opin Otolaryngol Head Neck Surg. 2023 Aug 1;31(4):269-275. doi: 10.1097/MOO.0000000000000900. Epub 2023 May 3. Management of osteosarcoma of the head and neck. Sharin F(1), Pai A(2), Mair M(1). Author information: (1)University hospital of Leicester, Leicester, UK. (2)HCG Hospital, Mumbai, India. PURPOSE OF REVIEW: There is no clear consensus guideline that specifies the optimum course of treatment for adult head and neck osteosarcoma (HNO) because of its rarity. The review's goal is to examine the most recent research on the presentation, diagnosis, prognosis, and therapy of head and neck osteosarcoma. RECENT FINDINGS: Due to overlapping symptoms with various benign disorders of the lower jaw and midface bone, these patients present with a noticeable delay. The greatest results for these malignancies can be achieved with surgery with sufficient margins. However, it may not be able to achieve sufficient margins in tumours of the midface and skull base, and the significance of adjuvant radiation/chemotherapy needs to be investigated. The use of adjuvant radiation in instances with an advanced stage, poor prognostic indicators, and inadequate resection is supported by evidence. Nonetheless, there are divergent opinions regarding the advantages of chemotherapy in adjuvant and neoadjuvant conditions, and further multicentric randomized control trials are required to provide robust evidence. SUMMARY: Multimodality treatments seem to yield better results for advanced HNO with adverse features and incomplete resections. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MOO.0000000000000900